Chinese pharma giant Hengrui launches new company for globalization play — with a Merck KGaA vet at the helm
It is not uncommon for a large company to want to expand its reach internationally and this is typically done by partnering with companies to test the water or establishing a satellite office and then getting to work on some projects. However, a major Chinese pharma is going all in.
Jiangsu Hengrui has launched Luzsana Biotechnology to serve as an arm to develop and deliver therapeutics outside of the Chinese market. Serving as a wholly owned subsidiary of Hengrui Pharma, Luzsana will be provided Hengrui’s pipeline of programs, spanning over 250 clinical studies, to develop and eventually commercialize.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.